spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  amyloidosis 

 HSMN NewsFeed - 8 Jun 2026
Protego Biopharma Appoints Jae B. Kim, MD, as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Jul 2025
Ultromics Lands $55M Series C to Tackle Undiagnosed Heart Failure at Scale
Devices Cardiology Venture Capital
 HSMN NewsFeed - 29 Dec 2021
Ionis and AstraZeneca close deal to develop and commercialize eplontersen
Biopharmaceuticals
 HSMN NewsFeed - 12 Jul 2021
Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Apr 2021
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
Biopharmaceuticals Neurology
 HSMN NewsFeed - 14 Sep 2020
Attralus Launches with $25 Million Series A Financing from venBio Partners to Transform Treatment for Patients with Systemic Amyloidosis
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 31 Aug 2020
Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 17 Apr 2020
PTC Therapeutics Announces New Leadership Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jan 2020
Lilly plans donation of 200,000 insulin KwikPens over next three years to support lower-income communities
Biopharmaceuticals Drug Delivery Endocrinology
 HSMN NewsFeed - 9 Jan 2020
Ionis Appoints Onaiza Cadoret-Manier As Chief Corporate Development and Commercial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 20 Sep 2018
Dr. Jared Gollob Joins Kymera Therapeutics as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jul 2018
New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI(TM) (inotersen) for the Treatment of Hereditary ATTR Amyloidosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 18 Jun 2018
Ionis Pharmaceuticals Appoints Damien McDevitt as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Apr 2018
Eidos Therapeutics completes $64M Series B financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 15 Mar 2018
Ionis and Akcea Partner to Commercialize Inotersen for hATTR
Biopharmaceuticals Licensing
 HSMN NewsFeed - 9 Nov 2017
Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 Nov 2017
Ionis Announces Management Transitions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2017
SPINRAZA(R) (nusinersen) Approved in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 15 May 2017
Ionis Pharmaceuticals Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS-TTR Rx) Meets Both Primary Endpoints
Biopharmaceuticals
 HSMN NewsFeed - 24 Feb 2017
CHMP Issues Positive Opinion Recommending DARZALEX(R) (daratumumab) for Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Dec 2016
SPINRAZA(TM) (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Nov 2016
Conditional Approval from the European Commission to Treat Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Aug 2016
Takeda Receives Marketing Authorization in Canada for NINLARO(TM) (ixazomib) in Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Apr 2016
Novartis Receives Three FDA Breakthrough Therapy Designations for IlaristTo Treat Rare Types of Periodic Fever Syndromes
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Mar 2016
Cairn Diagnostics Launches FDA-Approved Spirulina Gastric Emptying Breath Test for Gastroparesis
Diagnostics Gastroenterology Product Launch
 HSMN NewsFeed - 19 Jan 2016
Akcea Therapeutics Appoints Louis St. L. O'Dea as Chief Medical Officer
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 5 Jan 2016
Ionis Pharmaceuticals Receives Orphan Drug Designation from the US FDA for IONIS-HTT Rx for the Treatment of Patients with Huntington's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 14 Jan 2015
NeuroPhage Expands Series D Financing To $27 Million
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 6 Jan 2015
Isis Pharmaceuticals Appoints Paula Soteropoulos As President And Chief Executive Officer Of Akcea Therapeutics
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Nov 2014
NeuroPhage Appoints Industry Veteran Franz Hefti, PhD, President/COO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jul 2014
Alnylam Elects Amy Schulman to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Mar 2014
NeuroPhage, Inc. Raises $17 Million In Series D Financing
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 13 Jan 2014
Alnylam and Genzyme Form Transformational Alliance for RNAi Therapeutics as Genetic Medicines
Biopharmaceuticals Licensing
 HSMN NewsFeed - 27 Jun 2012
Alnylam Expands and Develops Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2012
Nephros Appoints John C. Houghton as President and Chief Executive Officer
Devices Personnel
 HSMN NewsFeed - 15 Feb 2012
FDA Accepts Pfizer’s New Drug Application for Tafamidis Meglumine, a Novel, Investigational Treatment for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 17 Nov 2011
Pfizer’s Vyndaqel(R) (tafamidis) First Therapy Approved in the European Union for the Rare and Fatal Neurodegenerative Disease Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 29 Jun 2011
Alnylam Files Answer and Counterclaim Related to Tekmira Lawsuit
Biopharmaceuticals Litigation
 HSMN NewsFeed - 13 Jun 2011
Alnylam Appoints Akshay Vaishnaw as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Dec 2010
Alnylam Elects Marsha Fanucci to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Sep 2010
Pfizer to Acquire FoldRx Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 2 Jun 2010
Alnylam Strengthens Management Team with New Key Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 May 2010
FoldRx Pharmaceuticals Appoints Dr. Georges Gemayel as Executive Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jan 2010
Alnylam Provides Key Goals and Guidance for Next 12 to 18 Months
Biopharmaceuticals
 HSMN NewsFeed - 2 Jul 2009
Nephros Receives 510k Approval for Dual Stage Ultrafilters
Devices FDA
 HSMN NewsFeed - 9 Jun 2009
William Aliski Named FoldRx Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Feb 2009
Nephros Provides Update on 510k Applications
Devices FDA
 HSMN NewsFeed - 21 Jan 2009
Alnylam and Collaborators at Harvard Medical School Demonstrate In Vivo Silencing of Key Genes Implicated in the Transmission of Herpes Simplex Virus-2 (HSV-2)
Biopharmaceuticals
 HSMN NewsFeed - 20 Jan 2009
Alnylam Provides Update on Kreutzer-Limmer Patent Family
Biopharmaceuticals
 HSMN NewsFeed - 17 Sep 2008
Nephros Appoints James S. Scibetta as Chairman of Board of Directors
Devices Personnel
 HSMN NewsFeed - 17 Sep 2008
Nephros Appoints Ernest A. Elgin III as President and Chief Executive Officer
Devices Personnel
 HSMN NewsFeed - 21 Apr 2008
Nephros Strengthens Commercialization Team with Addition of Marketing Executive
Devices Personnel
 HSMN NewsFeed - 13 Mar 2008
Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis
Biopharmaceuticals
 HSMN NewsFeed - 14 Dec 2007
Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Nov 2007
Nephros Receives Approval to Market OLpur(TM) MD Hemodiafilter Series in Canada
Devices Regulatory
 HSMN NewsFeed - 20 Nov 2007
Nephros Appoints James S. Scibetta to Board of Directors
Devices Personnel
 HSMN NewsFeed - 8 Nov 2007
Neurochem announces important initiatives to provide medical and health benefits to patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 25 Sep 2007
Nephros Raises $12.7 Million in New Financing
Devices Venture Capital
 HSMN NewsFeed - 28 Aug 2007
Neurochem provides information on cash position
Biopharmaceuticals Neurology
 HSMN NewsFeed - 24 Jul 2007
Neurochem granted Fast Track designation from U.S. FDA for tramiprosate (ALZHEMED(TM))
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 17 Jul 2007
Neurochem receives approvable letter for eprodisate (KIACTA(TM)) for treatment of AA amyloidosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Jun 2007
Tramiprosate (ALZHEMED(TM)) North American Phase III clinical trial progress update
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 Jun 2007
Neurochem receives third recommendation from European Data Safety Monitoring Board to continue Phase III clinical trial for tramiprosate (ALZHEMED(TM))
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 7 Jun 2007
Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA(TM)) Treatment for Patients with Amyloid A (AA) Amyloidosis
Biopharmaceuticals
 HSMN NewsFeed - 11 Apr 2007
Neurochem's eprodisate (KIACTA(TM)) PDUFA date extended three months by FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Feb 2007
Neurochem receives second recommendation from European Data Safety Monitoring Board to continue Phase III clinical trial for tramiprosate (ALZHEMED(TM))
Biopharmaceuticals Neurology
 HSMN NewsFeed - 1 Feb 2007
Neurochem announcement regarding the completion of its North American phase III clinical trial for tramiprosate (ALZHEMED(TM)) for the treatment of Alzheimer's disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Jan 2007
Nephros Receives Conditional Approval from the FDA of Investigational Device Exemption Application
Devices FDA
 HSMN NewsFeed - 8 Dec 2006
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Nov 2006
Neurochem receives recommendations from data safety monitoring boards to continue phase III clinical trials for tramiprosate (ALZHEMED(TM))
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Nov 2006
Tramiprosate (ALZHEMED(TM)) Phase II Clinical Results Published in Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Oct 2006
Multi-Center Study Concludes Nephros Mid-Dilution Hemodiafiltration Therapy Achieves Higher Clearance of Low Molecular Weight Proteins
Devices
 HSMN NewsFeed - 16 Oct 2006
Neurochem submits a complete response to FDA approvable letter for KIACTA(TM)
Biopharmaceuticals
 HSMN NewsFeed - 5 Oct 2006
Nephros Announces Positive Results of Clinical Study for Olpur MD190 Mid-Dilution Hemodiafiltration Filter
Devices
 HSMN NewsFeed - 30 May 2006
FoldRx Pharmaceuticals Closes $43 Million Series B Financing
Biopharmaceuticals Venture Capital
Return to NewsFeed  

 Additional items found! 29

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 29 additional stories matching:
amyloidosis
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!